RAPT Therapeutics (RAPT) Income towards Parent Company (2020 - 2023)
Historic Income towards Parent Company for Therapeutics (RAPT) over the last 4 years, with Q4 2023 value amounting to -$33.2 million.
- Therapeutics' Income towards Parent Company fell 3596.25% to -$33.2 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$33.2 million, marking a year-over-year increase of 7191.57%. This contributed to the annual value of -$127.1 million for FY2023, which is 4809.95% down from last year.
- Therapeutics' Income towards Parent Company amounted to -$33.2 million in Q4 2023, which was down 3596.25% from -$33.9 million recorded in Q3 2023.
- Therapeutics' 5-year Income towards Parent Company high stood at -$12.4 million for Q2 2020, and its period low was -$33.9 million during Q3 2023.
- Its 4-year average for Income towards Parent Company is -$20.9 million, with a median of -$18.8 million in 2021.
- In the last 5 years, Therapeutics' Income towards Parent Company plummeted by 1622.97% in 2022 and then tumbled by 5646.74% in 2023.
- Over the past 4 years, Therapeutics' Income towards Parent Company (Quarter) stood at -$12.7 million in 2020, then plummeted by 40.79% to -$17.9 million in 2021, then tumbled by 36.27% to -$24.4 million in 2022, then crashed by 35.96% to -$33.2 million in 2023.
- Its Income towards Parent Company stands at -$33.2 million for Q4 2023, versus -$33.9 million for Q3 2023 and -$28.4 million for Q2 2023.